The worldwide incidence of melanoma has risen rapidly in the past 50 years and is a considerable public health burden in the United States, with significant financial implications. Studies have demonstrated the potential anticarcinogenic effects of antihypertensive agents, specifically beta-blockers, in patients with prostate cancer, breast cancer, and lately cutaneous malignant melanoma. This article explores the empirical clinical evidence of propranolol's anticarcinogenic effects on melanoma and the chemoprotective mechanisms of beta-blockers and other agents that have been used to modify melanoma progression.
|Original language||English (US)|
|Number of pages||5|
|Journal||JAAPA : official journal of the American Academy of Physician Assistants|
|State||Published - Jun 1 2019|
ASJC Scopus subject areas
- Nurse Assisting